Contineum Therapeutics, Inc. (NASDAQ: CTNM) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT CONTINEUM THERAPEUTICS, INC.

Contineum Therapeutics, Inc. (NASDAQ: CTNM)
Listen to this Section


$11.84
-0.5050 ( -4.09% ) 203.5K

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Market Data


Open $11.84
Previous Close $12.34
Volume 203.5K
Market Cap $461.35M
Day Range $11.84 - $12.53
52 Week Range $3.57 - $16.33
Shares Outstanding 37.39M
Change % -4.09%
Net Change ▼ -0.5050
Insider Ownership 0.00%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2024
CountryUnited States
UnderwriterGoldman Sachs, Morgan Stanley, Stifel, RBC Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: -202,300.00

Date Type Amount Purchased Purchaser
2024-08-14 Sale -12800.00 Huhn Stephen L.
2024-06-24 Sale -29500.00 Boyce Sarah
2024-06-03 Sale -160000.00 Healy John Stephen

SEC Filings


Form Type Description Pages Date
8-k 8K-related 15 Oct 30, 2025
10-q Quarterly Reports 65 Oct 30, 2025
8-k 8K-related 25 Sep 18, 2025
8-k 8K-related 15 Aug 05, 2025
10-q Quarterly Reports 68 Aug 05, 2025
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 26, 2025

Latest News


× Before browsing our site, please accept our cookies policy